Biotech Values

[jbog]

The FTC said the deal would allow Amgen to “entrench the monopoly positions” of Horizon’s eye and gout drugs.

The agency said that neither of those treatments face any competition today and that Amgen would have a strong incentive to prevent any potential rivals from introducing similar drugs.

“The FTC won’t hesitate to challenge mergers that enable pharmaceutical conglomerates to entrench their monopolies at the expense of consumers and fair competition,” FTC Bureau of Competition Director Holly Vedova said.